Wednesday, September 3, 2025

Latest

Numinus Wellness’ Study On MDMA-Assisted Therapy For PTSD Gets Health Canada Nod

Numinus Wellness Inc. (TSXV: NUMI) announced today that it has secured approval from Health Canada to conduct its feasibility study on MDMA-assisted therapy to treat post-traumatic stress disorder. The health department recently issued a “letter of no objection”, allowing the proposed study to proceed.

The single-arm, open-label safety and feasibility study is sponsored by the Multidisciplinary Association for Psychedelic Studies through its subsidiary MAPS Public Benefit Corporation. 

In May 2021, MAPS reported the results from the Phase 3 clinical trial testing the efficacy and safety of MDMA-assisted therapy for PTSD. The results demonstrated that 88% of the participants that received the experimental sessions experienced clinically significant reduction in symptoms, with 67% no longer qualifying for a PTSD diagnosis compared to only 32% in the placebo group.

Following the federal regulatory approval, the company is gearing its study preparations to train staff, import medication, and obtain ethical approval related to COVID-19 protocols.

Beyond this study, the company is also undertaking further studies to assess the safety and psychoactive properties of the lab-produced extract from a Psilocybe mushroom product.

Numinus Wellness last traded at $1.14 on the TSX Venture.


Information for this briefing was found via Numinus Wellness. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Goliath Resources Hits 10.60 g/t Gold Over 22.82 Metres, Highest Grade Results In Third Distinct Rock Package At Surebet Discovery

Four Countries Control the Fertilizer That Feeds the World | Sage Potash

$10,000 Gold Is Just A Question of Time | Florian Grummes

Recommended

Afghanistan Quake Deaths Pass 1,400

Sage Potash Secures US$14 Million USDA Grant For Flagship Project

Related News

Numinus Wellness Successfully Extracts Psilocybin From Mushrooms

Numinus Wellness (TSXV: NUMI) this morning announced that it has completed the extraction of psilocybe...

Thursday, December 17, 2020, 08:26:09 AM

Numinus Wellness Announces Expansion To Research Lab

Numinus Wellness (TSXV: NUMI) has expansion on its mind. The company this morning announced that...

Tuesday, March 9, 2021, 08:18:23 AM

Numinus Wellness To Undertake Phase 1 Study Of Psilocybin Extract

Numinus Wellness (TSXV: NUMI) is undertaking further studies of its psilocybin products. The company this...

Monday, April 26, 2021, 07:10:35 AM

Numinus Wellness To Acquire MedBright AI In Bid To Add Artificial Intelligence To Portfolio

Numinus Wellness (TSX: NUMI) is set to get into the artificial intelligence business. The firm...

Thursday, June 20, 2024, 09:41:47 AM

Numinus Wellness To Acquire Novamind In All Stock Transaction At $0.44 Per Share

Consolidation within the psychedelics space is getting underway, with the announcement this morning that Numinus...

Tuesday, April 12, 2022, 07:56:51 AM